Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study

Open access

Abstract

Background: Studies have indicated that individuals taking aspirin have a reduced risk of cancers and have also established chemo-preventive benefit of aspirin in colorectal cancer. However, research on the association between aspirin use and the survival in patients with lung cancer has revealed inconsistent results. In this study, we investigated the effect of aspirin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients. Methods: We identified a cohort of 38,842 patients diagnosed with NSCLC between 2000 and 2012 using the Taiwan’s National Health Insurance Research Database and used propensity score matching to reduce possible confounding factors. In total, 9864 patients (4932 matched pairs) were included in the matched cohort. Aspirin exposure was analyzed to identify a possible association with mortality in patients with inoperable NSCLC. Time-dependent Cox regression models were used to calculate the hazard ratios (HRs) and the 95% confidence intervals (95% CIs) that corresponded with aspirin exposure. Results: A total of 4979 patients used aspirin at the time of diagnosis of NSCLC. The median overall survival (OS) of the aspirin users was 1.73 (interquartile range, 0.94–3.53) years compared with the 1.30 (interquartile range, 0.69–2.62) years of the non-aspirin users. The Cox proportional hazard model with the time-dependent covariate revealed that aspirin use was associated with a significantly longer OS (HR: 0.83, 95.0% CI: 0.80–0.86). After controlling the sociodemographic characteristics (age, sex, income, and level of urbanization) and lung cancer treatments by propensity score matching, the aspirin users still had a significantly longer OS than the non-aspirin users (HR: 0.79, 95.0% CI: 0.75–0.83). Conclusion: Aspirin use is associated with a longer OS in patients with inoperable NSCLC, suggesting that aspirin has a potential anticancer effect. These results warrant further randomized clinical trials to evaluate the actual role of aspirin in the treatment of NSCLC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-021-08999-8

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of patient enrollment process of the study cohort. ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NSCLC, non-small cell lung cancer
Fig. 1 Flow chart of patient enrollment process of the study cohort. ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NSCLC, non-small cell lung cancerCC BY · PubMed Central
Fig. 2 Kaplan-Meier curves of overall survival for patients with or without aspirin in the matched cohort. Aspirin use was associated with a significantly longer overall survival
Fig. 2 Kaplan-Meier curves of overall survival for patients with or without aspirin in the matched cohort. Aspirin use was associated with a significantly longer overall survivalCC BY · PubMed Central
Fig. 3 Subgroup analysis of adjusted hazard ratios (HRs) of risk factors for aspirin-related mortality. Aspirin use was associated with a significantly longer OS (HR: 0.83, 95.0% CI: 0.80–0.86). The survival benefit of aspirin use was maintained after propensity score matching at a ratio of 1:1 (HR: 0.79, 95.0% CI: 0.75–0.83)
Fig. 3 Subgroup analysis of adjusted hazard ratios (HRs) of risk factors for aspirin-related mortality. Aspirin use was associated with a significantly longer OS (HR: 0.83, 95.0% CI: 0.80–0.86). The survival benefit of aspirin use was maintained after propensity score matching at a ratio of 1:1 (HR: 0.79, 95.0% CI: 0.75–0.83)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Gann PH, Manson JE, Glyn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomised trial. J Natl Cancer Inst. 1993;85:1220–4. · DOI · Paper page

Cited by

See all 9

Metadata

Authors
Chuang, M.-C., Yang, Y.-H., Hsieh, M.-J., Lin, Y.-C., Yang, T.-M., Chen, P.-C., & Hung, M.-S.
Affiliations
  • Chang Gung University (TW)
  • National Taiwan University (TW)
  • Chang Gung University of Science and Technology (TW)
Corresponding author
Hung, Ming-Szu
Venue
BMC Cancer
Published
2021-11-22
Volume
21
Issue
1
Pages
1257-1257
ISSN
1471-2407 (ISSN-L)
OpenAlex
W3217003007
Cited by
9
References
50
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 1 · 2022: 1
FWCI
0.44
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Chang Gung Medical Foundation
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
aspirin, non-small cell lung cancer, inoperable lung cancer, overall survival, mortality, chemoprevention, nonsteroidal anti-inflammatory drugs
MeSH terms
Age Factors, Aged, Anti-Inflammatory Agents, Non-Steroidal, Antineoplastic Agents, Aspirin, Carcinoma, Non-Small-Cell Lung, Female, Humans, Income, Lung Neoplasms, Male, Middle Aged, National Health Programs, Retrospective Studies, Sex Factors, Taiwan, Urbanization, Cohort Studies, Confidence Intervals, Proportional Hazards Models, Propensity Score

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study. https://app.cochat.ai/papers/10.1186/s12885-021-08999-8
The paper
Chuang, M.-C., Yang, Y.-H., Hsieh, M.-J., Lin, Y.-C., Yang, T.-M., Chen, P.-C., & Hung, M.-S. (2021). The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study. BMC Cancer. https://doi.org/10.1186/s12885-021-08999-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.